Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

J. Cummings, M. Ranson, E. Lacasse, J. R. Ganganagari, M. St-Jean, G. Jayson, J. Durkin, C. Dive

Research output: Contribution to journalArticlepeer-review

Abstract

Data are presented on pharmacodynamic (PD) method validation and preliminary clinical qualification of three PD biomarker assays. M65 Elisa, which quantitates different forms of circulating cytokeratin 18 (CK18) as putative surrogate markers of both apoptotic and nonapoptotic tumour cell death, was shown to be highly reproducible: calibration curve linearity r 2=0.996, mean accuracy >91% and mean precision
Original languageEnglish
Pages (from-to)42-48
Number of pages6
JournalBritish Journal of Cancer
Volume95
Issue number1
DOIs
Publication statusPublished - 3 Jul 2006

Keywords

  • Biomarker variability
  • M30 Apoptosense
  • M65 Elisa
  • Quantitative RT-PCR
  • Stability
  • Validation

Fingerprint

Dive into the research topics of 'Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP'. Together they form a unique fingerprint.

Cite this